Phase I/II Trial of Rhenium 188-P2045 in Small Cell Lung Cancer and Other Advanced Neuroendocrine Carcinomas

Exclusion Criteria

• •Merkel cell carcinoma
• •Leptomeningeal disease or carcinomatous meningitis
• •Chemotherapy or radiotherapy within 3 weeks prior to entering the study or those who have not recovered from adverse events due to agents administered \> 3 weeks earlier.
• •If the patient was receiving an oral agent, at least 4 half lives should have elapsed.
• •Cannot receive any other investigational agent at the time of registration. At least 3 weeks should have elapsed since administration of an IV investigational agent or 4 half lives for an oral investigational agent.
• •At least 28 days should have elapsed since administration of a long acting somatostatin analogue.
• •Patients who have received external beam radiation to more than 20% of marrow.
• •No prior radiation to the kidneys.
• •Receiving long term immunosuppressive medications for rheumatologic or other disease (e.g. low dose methotrexate, mecaptopurine etc).
• •History of allergic reactions attributed to compounds of similar chemical or biologic composition to octreotide or other somatostatin analogues.
• •Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements.
• •Pregnant or nursing (due to the potential for congenital abnormalities and the potential of this regimen to harm nursing infants.)